Scarica l'app Stockscreener
6.345
1.11%
-0.085
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals Experiences 10.7% Stock Price Surge Amid Strong Investor Interest - AInvest
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? - The Globe and Mail
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities - The Motley Fool
Is Recursion Pharmaceuticals Inc. a good long term investmentFree Investment Case Studies - jammulinksnews.com
What drives Recursion Pharmaceuticals Inc. stock priceRapid growth trajectories - jammulinksnews.com
Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market - AInvest
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism - FinancialContent
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo.co
What analysts say about Recursion Pharmaceuticals Inc. stockOver 200% growth - jammulinksnews.com
Top 2 Health Care Stocks You May Want To Dump This Quarter - Benzinga
(RXRX) Trading Signals - news.stocktradersdaily.com
Here's Why Shares in Recursion Pharmaceuticals Surged Today - AOL.com
Recursion Pharmaceuticals Surges 58.77% in Trading Volume Reaching 207th Position in Market Rankings - AInvest
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX) - FinancialContent
RXRX Surges Ahead: Is It Time to Jump In? - timothysykes.com
Recursion Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment - Nasdaq
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Price Surge - Nasdaq
Recursion Pharmaceuticals’ Stock Soars as It Gains Full Rights to REV102 - StocksToTrade
Recursion Pharmaceuticals Surges 5.8%: Will Momentum Continue? - AInvest
Why Is Recursion Pharma Stock Surging On Monday? - Benzinga
Recursion Pharmaceuticals (RXRX) Stock Jumps After Acquiring Full Rights to REV102 for Rare Bone Disorder - FinancialBuzz.com
Recursion Pharmaceuticals Stock Soars Amid Investor Optimism - TipRanks
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Recursion Bets On AI Drug Discovery Despite Volatile Year - Finimize
Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month - Yahoo Finance
Recursion Pharmaceuticals Experiences Surge in Bullish Options Activity with Implied Volatility Rising 9 Points to 110.01%. - AInvest
Recursion Pharmaceuticals (RXRX) Is Up 10.6% After Expanding AI Partnerships and Acquiring Exscientia - simplywall.st
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
Recursion Pharmaceuticals Surges to 360th in Market Rankings with $312 Million Trading Volume - AInvest
Recursion Pharmaceutical’s Latest Acquisition: A Game Changer? - timothysykes.com
Why Did Recursion Soar 12%? - timothysykes.com
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Soars After Strategic Acquisition - StocksToTrade
Why Recursion Pharmaceuticals Stock is Climbing - TipRanks
Recursion Pharmaceuticals Acquires Full Rights to REV102, Bolstering Stock Performance - timothysykes.com
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - MSN
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts - MSN
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Yahoo.co
3.28%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):